2C2-NBOMe, also known as 2C-MMDA-2-NBOMe or NBOMe-MMDPEA-2, is a phenethylamine derivative from the 25-NB (NBOMe) family. It is the NBOMe derivative of 2C-MMDA-2 (MMDPEA-2).

It acts as a potent agonist at the serotonin 5-HT2A receptor with weaker activity at 5-HT2B and 5-HT2C, and produces a head-twitch response in animal studies which often correlates with potential for psychedelic effects in humans.

It is related in structure to psychedelic phenethylamine derivatives such as MMDA-2 and lophophine (MMDPEA) and is the first phenethylamine derivative with a methylenedioxy substitution on the phenyl ring but no alkyl substitution on the alpha carbon, that has been shown to produce psychedelic-appropriate responding in animals.

The drug was first described in the literature by Jason Wallach and colleagues in 2022 and 2023. It is a controlled substance in Canada under phenethylamine blanket-ban language. The drug is not an explicitly controlled substance in the United States, but could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.

See also

External links